
AbbVie (ABBV) Stock
AbbVie Chart
Company Profile
Price: $193.04
Market Cap: $341.13B
Exchange: NYSE
CEO: Mr. Robert A. Michael CPA
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 50.00K
Headquarters: North Chicago, IL
Website: AbbVie
Business Summary
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie News
Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
Consumers Can Apply Today for a Chance to be Featured in an Upcoming Campaign by Natrelle® and Share Their Personal Stories. Natrelle® is the #1 Selected Breast Implant by Leading U.S. Physicians* Offering the Largest Range of Options For Every Curve, Every Shape, For Every BODY.

Buy, Sell, Or Hold ABBV Stock At $185?
AbbVie (NYSE: ABBV) recently released its Q4 results, with revenues and earnings comfortably above the street estimates. It reported sales of $15.1 billion and adjusted earnings of $2.16 per share, compared to the consensus estimates of $14.8 billion and $2.11, respectively.

2 Undervalued Dividend Stocks Ready For A Major Comeback
The economy is mixed - strong in some sectors, weak in others. I see value in cyclical stocks and healthcare, both lagging but poised for growth. One pick is a cyclical turnaround story with strong recovery potential. The other is a high-yield healthcare gem with anti-cyclical resilience. Both stocks offer market-beating potential, solid dividends, and long-term growth. They're perfect for balancing risk and reward in today's uncertain economy.

AbbVie Q4 Earnings: Strong Revenue Results, Ambitious Forecasts - A Buy With Caveats
AbbVie's Q4 and full-year 2024 earnings surpassed expectations, driven by strong performance from Skyrizi and Rinvoq, despite Humira's revenue decline due to patent expirations. Management's guidance for 2025 and beyond is bullish, projecting high single-digit revenue growth through 2029, with Skyrizi and Rinvoq expected to generate $31 billion in combined sales by 2027. AbbVie's M&A strategy faced setbacks, notably with the Cerevel acquisition, but the company remains optimistic about future approvals and growth in oncology and neuroscience.

AbbVie Q4 Earnings: Good 2025 Outlook Despite Enhanced Old And New Headwinds
AbbVie Inc. reported strong Q4 2024 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care, and this offset worse-than-expected Humira erosion. 2025 guidance includes $59 billion in revenue and $12.12-$12.32 adjusted EPS, and includes a worse outlook for Humira and additional headwinds from the Medicare Part D benefit redesign. Management expects high single-digit revenue growth through 2029, and over the next eight years, as there are no major products losing exclusivity throughout this period.

AbbVie Inc. (ABBV) Q4 2024 Earnings Call Transcript
AbbVie Inc. (NYSE:ABBV ) Q4 2024 Earnings Conference Call January 31, 2025 9:00 AM ET Company Participants Liz Shea - Senior Vice President, Investor Relations Rob Michael - Chief Executive Officer Jeff Stewart - Executive Vice President, Chief Commercial Officer Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer Scott Reents - Executive Vice President, Chief Financial Officer Carrie Strom - Senior Vice President of AbbVie, and President of Global Allergan Aesthetics Conference Call Participants Vamil Divan - Guggenheim Securities Chris Schott - J.P. Morgan Geoff Meacham - Citigroup Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Steve Scala - TD Cowen Tim Anderson - Bank of America Chris Raymond - Piper Sandler Trung Huynh - UBS Chris Shibutani - Goldman Sachs Operator Good morning and thank you for standing by.

AbbVie shares rise as new drug sales offset Humira decline in Q4
Abbvie Inc (NYSE:ABBV) shares surged after the company posted a positive financial report for the fourth quarter, with sales growth of newer drugs offsetting a steep decline in Humira revenue. Earnings per share of $2.16 topped estimates of $2.13, but marked a decline from $2.79 in the year-ago quarter.

AbbVie Investors Trigger Trend-Following Signal: Time to Load Up
AbbVie NYSE: ABBV is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira's patent cliff are behind it, with Skyrizi, Rinvoq, and the diversified portfolio of products gaining traction.

Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs
AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug that now faces stiff competition.

AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to 2024 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $56.334 Billion, an Increase of 3.7 Percent on a Reported Basis and 4.6 Percent on an Operational Basis Full-Year Global Net Revenues from the Immunology Portfolio Were $26.682 Billion, an Increase of 2.1 Percent on a Reported Basis, or 2.9 Percent on an Operational Basis; Global Humira Net Revenues Were $8.993 Billion; Global Skyrizi Net Revenues Were $11.718 Billion; Global Rinvoq Net Revenues Were $5.971 Billion Full-Year Global Net Revenues from the Oncology Portfolio Were $6.555 Billion, an Increase of 10.8 Percent on a Reported Basis, or 12.0 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $3.347 Billion; Global Venclexta Net Revenues Were $2.583 Billion Full-Year Global Net Revenues from the Neuroscience Portfolio Were $8.999 Billion, an Increase of 16.6 Percent on a Reported Basis, or 16.9 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $3.283 Billion; Global Vraylar Net Revenues Were $3.267 Billion ; Combined Global Ubrelvy and Qulipta Net Revenues were $1.664 Billion Full-Year Global Net Revenues from the Aesthetics Portfolio Were $5.176 Billion, a Decrease of 2.2 Percent on a Reported Basis, or 0.6 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $2.720 Billion; Global Juvederm Net Revenues Were $1.177 Billion Reports Fourth-Quarter Diluted Loss Per Share of $0.02 on a GAAP Basis, Inclusive of the Recent Partial Intangible Asset Impairment Charge Related to Emraclidine; Adjusted Diluted EPS of $2.16; These Results Include an Unfavorable Impact of $0.88 Per Share Related to Fourth-Quarter 2024 Acquired IPR&D and Milestones Expense Delivers Fourth-Quarter Net Revenues of $15.102 Billion, an Increase of 5.6 Percent on a Reported Basis and 6.1 Percent on an Operational Basis Provides 2025 Adjusted Diluted EPS Guidance Range of $12.12 to $12.32; Excludes Any Unfavorable Impact Related to Acquired IPR&D and Milestones Expense Reaffirms Expectations for High Single-Digit Compound Annual Revenue Growth Rate through 2029; Raises 2027 Combined Sales Outlook for Skyrizi and Rinvoq to More Than $31 Billion; Updates Outlook for Aesthetics to Deliver High Single-Digit Compound Annual Revenue Growth Rate from 2025 through 2029 NORTH CHICAGO, Ill., Jan. 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2024.

I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems from a fundamental truth: A sustainable high dividend yield often serves as a powerful indicator of intrinsic value.

Why AbbVie Stock Popped While the Market Flopped on Monday
Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (ABBV 3.88%) wasn't one of them. The storied pharmaceutical company saw its share price rise by almost 4%, on the back of a pair of pre-earnings price target bumps from analysts.

AbbVie Earnings
This section highlights AbbVie's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q4 | 2024 | 2025-01-31 | $2.98 | $2.16 |
Read Transcript | Q3 | 2024 | 2024-10-30 | $2.92 | $3.00 |
Read Transcript | Q2 | 2024 | 2024-07-25 | $2.57 | $2.65 |
Read Transcript | Q1 | 2024 | 2024-04-26 | $2.26 | $2.31 |
Read Transcript | Q4 | 2023 | 2024-02-02 | $2.76 | $2.79 |
Read Transcript | Q3 | 2023 | 2023-10-27 | $2.86 | $2.95 |
Read Transcript | Q2 | 2023 | 2023-07-27 | $2.79 | $2.91 |
Read Transcript | Q1 | 2023 | 2023-04-27 | $2.44 | $2.46 |
Financial Statements
Access annual & quarterly financial statements for AbbVie, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Revenue | $54.32B | $58.05B | $56.20B | $45.80B | $33.27B |
Cost of Revenue | $20.41B | $17.41B | $17.45B | $15.39B | $7.44B |
Gross Profit | $33.90B | $40.64B | $38.75B | $30.42B | $25.83B |
Gross Profit Ratio | 62.42% | 70.00% | 68.96% | 66.41% | 77.64% |
Research and Development Expenses | $8.45B | $6.51B | $7.08B | $6.56B | $6.41B |
General and Administrative Expenses | $10.70B | $13.26B | $10.25B | $9.50B | $5.84B |
Selling and Marketing Expenses | $2.20B | $2.00B | $2.10B | $1.80B | $1.10B |
Selling General and Administrative Expenses | $12.87B | $15.26B | $12.35B | $11.30B | $6.94B |
Other Expenses | $- | $56.00M | $432.00M | $-5.61B | $-890.00M |
Operating Expenses | $21.15B | $21.83B | $19.86B | $17.86B | $12.46B |
Cost and Expenses | $41.56B | $39.94B | $38.27B | $34.44B | $20.28B |
Interest Income | $540.00M | $186.00M | $39.00M | $174.00M | $275.00M |
Interest Expense | $2.22B | $2.23B | $2.42B | $2.45B | $1.78B |
Depreciation and Amortization | $8.70B | $8.47B | $8.52B | $6.47B | $2.02B |
EBITDA | $17.31B | $31.42B | $28.28B | $21.15B | $16.26B |
EBITDA Ratio | 31.86% | 45.79% | 47.06% | 15.17% | 41.47% |
Operating Income | $12.76B | $18.12B | $17.92B | $11.36B | $12.98B |
Operating Income Ratio | 23.49% | 31.21% | 31.89% | 24.81% | 39.03% |
Total Other Income Expenses Net | $-6.51B | $-4.64B | $-4.93B | $-7.96B | $-4.56B |
Income Before Tax | $6.25B | $13.48B | $12.99B | $3.40B | $8.43B |
Income Before Tax Ratio | 11.51% | 23.21% | 23.11% | 7.42% | 25.33% |
Income Tax Expense | $1.38B | $1.63B | $1.44B | $1.22B | $544.00M |
Net Income | $4.86B | $11.84B | $11.54B | $4.62B | $7.88B |
Net Income Ratio | 8.95% | 20.39% | 20.54% | 10.08% | 23.69% |
EPS | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 |
EPS Diluted | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 |
Weighted Average Shares Outstanding | 1.77B | 1.77B | 1.77B | 1.67B | 1.48B |
Weighted Average Shares Outstanding Diluted | 1.77B | 1.78B | 1.78B | 1.67B | 1.48B |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $14.46B | $14.46B | $12.31B | $14.30B | $13.93B | $13.87B | $12.22B | $15.12B | $14.81B | $14.58B | $13.54B | $14.89B | $14.34B | $13.96B | $13.01B | $13.86B | $12.90B | $10.43B | $8.62B | $8.70B |
Cost of Revenue | $4.21B | $2.18B | $4.08B | $2.39B | $6.49B | $4.24B | $3.99B | $4.17B | $5.02B | $4.17B | $4.05B | $4.32B | $4.39B | $4.52B | $4.21B | $4.68B | $5.05B | $3.71B | $1.94B | $2.01B |
Gross Profit | $10.25B | $12.29B | $8.23B | $11.91B | $7.44B | $9.62B | $8.24B | $10.95B | $9.79B | $10.41B | $9.49B | $10.57B | $9.95B | $9.44B | $8.80B | $9.17B | $7.85B | $6.71B | $6.68B | $6.70B |
Gross Profit Ratio | 70.87% | 84.95% | 66.84% | 83.32% | 53.44% | 69.42% | 67.39% | 72.42% | 66.10% | 71.41% | 70.07% | 70.98% | 69.39% | 67.60% | 67.62% | 66.20% | 60.86% | 64.40% | 77.47% | 76.95% |
Research and Development Expenses | $2.13B | $1.92B | $1.94B | $1.92B | $1.72B | $1.73B | $2.29B | $1.79B | $1.61B | $1.61B | $1.50B | $1.83B | $1.67B | $1.80B | $1.78B | $1.89B | $1.71B | $1.58B | $1.38B | $1.54B |
General and Administrative Expenses | $- | $- | $- | $1.41B | $- | $- | $- | $1.42B | $- | $- | $- | $1.16B | $- | $- | $- | $1.43B | $- | $- | $1.70B | $1.95B |
Selling and Marketing Expenses | $- | $- | $- | $2.20B | $- | $- | $- | $2.00B | $- | $- | $- | $2.10B | $- | $- | $- | $1.80B | $- | $- | $- | $1.10B |
Selling General and Administrative Expenses | $4.21B | $3.34B | $3.30B | $3.61B | $3.37B | $3.27B | $3.04B | $3.42B | $3.30B | $5.41B | $3.13B | $3.26B | $3.08B | $3.16B | $2.84B | $3.23B | $2.85B | $3.53B | $1.70B | $1.95B |
Other Expenses | $82.00M | $-1.95B | $-586.00M | $-1.89B | $95.00M | $-1.41B | $-10.00M | $-1.00M | $229.00M | $-1.53B | $776.00M | $-216.00M | $-21.00M | $-2.66B | $395.00M | $-4.62B | $-115.00M | $-802.00M | $-72.00M | $-416.00M |
Operating Expenses | $6.42B | $7.21B | $5.24B | $7.42B | $5.09B | $4.83B | $5.32B | $5.21B | $5.15B | $6.85B | $4.62B | $5.09B | $5.26B | $4.90B | $4.62B | $5.12B | $4.55B | $5.11B | $3.07B | $2.60B |
Cost and Expenses | $10.63B | $10.46B | $9.51B | $11.11B | $11.65B | $9.35B | $9.46B | $9.62B | $10.21B | $11.29B | $8.82B | $9.81B | $10.04B | $9.52B | $8.91B | $10.11B | $9.65B | $9.67B | $5.02B | $4.75B |
Interest Income | $- | $220.00M | $207.00M | $186.00M | $157.00M | $98.00M | $99.00M | $90.00M | $63.00M | $24.00M | $9.00M | $9.00M | $11.00M | $9.00M | $10.00M | $11.00M | $10.00M | $18.00M | $135.00M | $104.00M |
Interest Expense | $591.00M | $726.00M | $660.00M | $564.00M | $555.00M | $552.00M | $553.00M | $566.00M | $560.00M | $556.00M | $548.00M | $580.00M | $596.00M | $615.00M | $632.00M | $629.00M | $630.00M | $632.00M | $563.00M | $559.00M |
Depreciation and Amortization | $2.08B | $2.13B | $2.07B | $2.08B | $2.23B | $2.26B | $2.13B | $2.16B | $2.21B | $2.05B | $2.05B | $1.98B | $2.13B | $2.20B | $2.21B | $2.06B | $2.29B | $1.55B | $559.00M | $509.00M |
EBITDA | $4.93B | $7.13B | $5.56B | $6.62B | $4.71B | $7.20B | $5.80B | $8.26B | $7.24B | $7.79B | $7.27B | $8.77B | $7.04B | $6.93B | $6.68B | $8.37B | $5.84B | $3.75B | $4.20B | $3.79B |
EBITDA Ratio | 34.11% | 35.15% | 41.13% | 29.25% | 17.53% | 48.85% | 40.04% | 50.65% | 45.96% | 13.93% | 50.01% | 47.38% | 44.85% | 47.58% | 48.56% | 41.98% | 42.99% | 22.13% | 48.29% | 51.30% |
Operating Income | $3.83B | $4.00B | $2.80B | $3.19B | $2.28B | $4.51B | $2.77B | $5.50B | $4.60B | $3.29B | $4.72B | $5.07B | $4.31B | $4.44B | $4.10B | $3.75B | $3.25B | $752.00M | $3.60B | $3.96B |
Operating Income Ratio | 26.49% | 27.64% | 22.73% | 22.34% | 16.38% | 32.55% | 22.64% | 36.39% | 31.08% | 22.59% | 34.84% | 34.09% | 30.02% | 31.81% | 31.54% | 27.08% | 25.23% | 7.21% | 41.80% | 45.45% |
Total Other Income Expenses Net | $-1.75B | $-1.85B | $-1.04B | $-1.98B | $-328.00M | $-1.90B | $-2.29B | $-2.54B | $-203.00M | $-2.11B | $212.00M | $-803.00M | $-618.00M | $-3.28B | $-236.00M | $-5.26B | $-755.00M | $-1.45B | $-505.00M | $-882.00M |
Income Before Tax | $2.08B | $2.15B | $1.75B | $1.21B | $1.95B | $2.61B | $475.00M | $2.96B | $4.40B | $1.18B | $4.93B | $4.27B | $3.69B | $1.16B | $3.87B | $-1.51B | $2.50B | $-693.00M | $3.10B | $3.07B |
Income Before Tax Ratio | 14.41% | 14.84% | 14.26% | 8.47% | 14.02% | 18.82% | 3.89% | 19.61% | 29.71% | 8.11% | 36.41% | 28.69% | 25.71% | 8.33% | 29.72% | -10.87% | 19.38% | -6.65% | 35.94% | 35.32% |
Income Tax Expense | $520.00M | $773.00M | $383.00M | $388.00M | $172.00M | $583.00M | $234.00M | $493.00M | $448.00M | $255.00M | $436.00M | $226.00M | $508.00M | $394.00M | $312.00M | $1.54B | $187.00M | $46.00M | $88.00M | $273.00M |
Net Income | $1.56B | $1.37B | $1.37B | $822.00M | $1.78B | $2.02B | $239.00M | $2.47B | $3.95B | $924.00M | $4.49B | $4.04B | $3.18B | $766.00M | $3.55B | $36.00M | $2.31B | $-738.00M | $3.01B | $2.80B |
Net Income Ratio | 10.80% | 9.47% | 11.12% | 5.75% | 12.77% | 14.60% | 1.96% | 16.35% | 26.66% | 6.34% | 33.17% | 27.17% | 22.17% | 5.49% | 27.31% | 0.26% | 17.89% | -7.08% | 34.92% | 32.18% |
EPS | $0.88 | $0.78 | $0.77 | $0.46 | $1.00 | $1.14 | $0.13 | $1.40 | $2.23 | $0.52 | $2.54 | $2.29 | $1.78 | $0.42 | $2.00 | $0.02 | $1.30 | $-0.45 | $2.02 | $1.89 |
EPS Diluted | $0.88 | $0.78 | $0.77 | $0.46 | $1.00 | $1.14 | $0.13 | $1.39 | $2.22 | $0.51 | $2.53 | $2.26 | $1.78 | $0.42 | $1.99 | $0.01 | $1.29 | $-0.45 | $2.02 | $1.88 |
Weighted Average Shares Outstanding | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.64B | 1.48B | 1.48B |
Weighted Average Shares Outstanding Diluted | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.78B | 1.78B | 1.78B | 1.78B | 1.78B | 1.78B | 1.78B | 1.78B | 1.77B | 1.78B | 1.77B | 1.65B | 1.48B | 1.49B |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $12.81B | $9.20B | $9.75B | $8.45B | $39.92B |
Short Term Investments | $2.00M | $28.00M | $84.00M | $30.00M | $- |
Cash and Short Term Investments | $12.82B | $9.23B | $9.83B | $8.48B | $39.92B |
Net Receivables | $11.15B | $11.25B | $9.98B | $8.82B | $5.43B |
Inventory | $4.10B | $3.58B | $3.13B | $3.31B | $1.81B |
Other Current Assets | $4.93B | $4.40B | $4.99B | $3.56B | $2.35B |
Total Current Assets | $33.00B | $28.46B | $27.93B | $24.17B | $49.52B |
Property Plant Equipment Net | $4.99B | $4.93B | $5.11B | $5.25B | $2.96B |
Goodwill | $32.29B | $32.16B | $32.38B | $33.12B | $15.60B |
Intangible Assets | $55.61B | $67.44B | $75.95B | $82.88B | $18.65B |
Goodwill and Intangible Assets | $87.90B | $99.59B | $108.33B | $116.00B | $34.25B |
Long Term Investments | $304.00M | $241.00M | $277.00M | $293.00M | $93.00M |
Tax Assets | $- | $- | $- | $- | $- |
Other Non-Current Assets | $8.51B | $5.57B | $4.88B | $4.85B | $2.29B |
Total Non-Current Assets | $101.71B | $110.34B | $118.60B | $126.39B | $39.60B |
Other Assets | $- | $- | $- | $- | $- |
Total Assets | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B |
Account Payables | $3.69B | $2.93B | $2.88B | $2.28B | $1.45B |
Short Term Debt | $7.19B | $4.14B | $12.49B | $8.50B | $3.75B |
Tax Payables | $- | $- | $- | $- | $- |
Deferred Revenue | $- | $- | $- | $- | $- |
Other Current Liabilities | $26.96B | $22.47B | $19.82B | $17.88B | $10.38B |
Total Current Liabilities | $37.84B | $29.54B | $35.19B | $28.66B | $15.59B |
Long Term Debt | $52.96B | $59.91B | $64.93B | $78.41B | $63.25B |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $- | $2.19B | $3.01B | $3.65B | $1.13B |
Other Non-Current Liabilities | $33.52B | $32.07B | $30.97B | $30.40B | $18.46B |
Total Non-Current Liabilities | $86.47B | $91.98B | $95.90B | $108.81B | $81.70B |
Other Liabilities | $- | $- | $- | $- | $- |
Total Liabilities | $124.31B | $121.52B | $131.09B | $137.47B | $97.29B |
Preferred Stock | $- | $- | $- | $- | $- |
Common Stock | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M |
Retained Earnings | $-1.00B | $4.78B | $3.13B | $1.05B | $4.72B |
Accumulated Other Comprehensive Income Loss | $-2.31B | $-2.20B | $-2.90B | $-3.12B | $-3.60B |
Other Total Stockholders Equity | $13.65B | $14.65B | $15.16B | $15.12B | $-9.31B |
Total Stockholders Equity | $10.36B | $17.25B | $15.41B | $13.08B | $-8.17B |
Total Equity | $10.40B | $17.29B | $15.44B | $13.10B | $-8.17B |
Total Liabilities and Stockholders Equity | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B |
Minority Interest | $37.00M | $33.00M | $28.00M | $21.00M | $- |
Total Liabilities and Total Equity | $134.71B | $138.81B | $146.53B | $150.56B | $89.11B |
Total Investments | $306.00M | $269.00M | $361.00M | $323.00M | $93.00M |
Total Debt | $59.38B | $63.27B | $76.68B | $86.06B | $66.73B |
Net Debt | $46.57B | $54.07B | $66.94B | $77.61B | $26.80B |
Balance Sheet Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $7.26B | $13.13B | $18.07B | $12.81B | $13.29B | $8.76B | $6.71B | $9.20B | $11.83B | $8.52B | $6.10B | $9.75B | $12.18B | $8.55B | $9.76B | $8.45B | $7.89B | $6.02B | $41.14B | $39.92B |
Short Term Investments | $28.00M | $27.00M | $2.00M | $2.00M | $3.00M | $7.00M | $11.00M | $28.00M | $47.00M | $1.44B | $1.47B | $84.00M | $67.00M | $54.00M | $22.00M | $30.00M | $60.00M | $23.00M | $- | $- |
Cash and Short Term Investments | $7.29B | $13.16B | $18.07B | $12.82B | $13.29B | $8.77B | $6.72B | $9.23B | $11.88B | $9.96B | $7.57B | $9.83B | $12.25B | $8.60B | $9.78B | $8.48B | $7.95B | $6.04B | $41.14B | $39.92B |
Net Receivables | $11.47B | $11.72B | $11.95B | $11.15B | $11.41B | $11.49B | $11.47B | $11.25B | $10.74B | $11.24B | $10.73B | $9.98B | $9.28B | $9.91B | $9.59B | $8.82B | $8.42B | $8.35B | $6.36B | $5.43B |
Inventory | $4.45B | $4.22B | $4.25B | $4.10B | $3.98B | $4.05B | $3.83B | $3.58B | $3.17B | $3.40B | $3.48B | $3.13B | $3.09B | $3.39B | $3.27B | $3.31B | $3.47B | $4.06B | $1.84B | $1.81B |
Other Current Assets | $4.58B | $4.72B | $4.61B | $4.93B | $4.54B | $4.54B | $4.46B | $4.40B | $4.57B | $4.51B | $4.72B | $4.99B | $4.33B | $4.10B | $3.93B | $3.56B | $3.17B | $2.80B | $2.41B | $2.35B |
Total Current Assets | $27.79B | $33.82B | $38.87B | $33.00B | $33.22B | $28.85B | $26.49B | $28.46B | $30.36B | $29.10B | $26.51B | $27.93B | $28.96B | $26.00B | $26.57B | $24.17B | $23.01B | $21.26B | $51.76B | $49.52B |
Property Plant Equipment Net | $5.14B | $5.02B | $4.98B | $4.99B | $4.93B | $4.94B | $4.93B | $4.93B | $4.89B | $4.96B | $5.08B | $5.11B | $5.13B | $5.16B | $5.19B | $5.25B | $4.99B | $4.91B | $2.96B | $2.96B |
Goodwill | $35.30B | $33.39B | $33.43B | $32.29B | $32.09B | $32.22B | $32.22B | $32.16B | $31.73B | $32.03B | $32.30B | $32.38B | $32.30B | $32.40B | $32.35B | $33.12B | $42.80B | $42.67B | $15.56B | $15.60B |
Intangible Assets | $66.65B | $60.24B | $62.23B | $55.61B | $58.60B | $62.86B | $64.85B | $67.44B | $68.72B | $71.82B | $73.99B | $75.95B | $77.46B | $79.34B | $81.29B | $82.88B | $74.64B | $76.46B | $18.20B | $18.65B |
Goodwill and Intangible Assets | $101.94B | $93.63B | $95.65B | $87.90B | $90.69B | $95.09B | $97.07B | $99.59B | $100.45B | $103.85B | $106.28B | $108.33B | $109.75B | $111.74B | $113.64B | $116.00B | $117.44B | $119.13B | $33.76B | $34.25B |
Long Term Investments | $267.00M | $272.00M | $305.00M | $304.00M | $275.00M | $288.00M | $257.00M | $241.00M | $235.00M | $244.00M | $260.00M | $277.00M | $272.00M | $266.00M | $305.00M | $293.00M | $246.00M | $225.00M | $78.00M | $93.00M |
Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Non-Current Assets | $8.29B | $9.20B | $9.07B | $8.51B | $7.09B | $6.20B | $5.80B | $5.57B | $5.38B | $5.03B | $5.08B | $4.88B | $4.75B | $4.81B | $4.79B | $4.85B | $3.94B | $4.01B | $2.64B | $2.29B |
Total Non-Current Assets | $115.64B | $108.12B | $110.00B | $101.71B | $103.00B | $106.52B | $108.06B | $110.34B | $110.96B | $114.09B | $116.70B | $118.60B | $119.90B | $121.97B | $123.93B | $126.39B | $126.61B | $128.27B | $39.44B | $39.60B |
Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Assets | $143.42B | $141.94B | $148.87B | $134.71B | $136.22B | $135.37B | $134.54B | $138.81B | $141.32B | $143.19B | $143.21B | $146.53B | $148.86B | $147.97B | $150.50B | $150.56B | $149.62B | $149.53B | $91.20B | $89.11B |
Account Payables | $- | $- | $- | $3.69B | $- | $- | $- | $2.93B | $- | $- | $- | $2.88B | $- | $- | $- | $2.28B | $- | $- | $- | $1.45B |
Short Term Debt | $12.57B | $12.59B | $10.20B | $7.19B | $5.12B | $5.20B | $2.80B | $4.14B | $9.21B | $11.93B | $9.95B | $12.49B | $6.67B | $7.90B | $11.35B | $8.69B | $4.78B | $5.37B | $3.76B | $3.87B |
Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Other Current Liabilities | $30.49B | $29.33B | $31.33B | $26.96B | $29.66B | $27.04B | $24.79B | $22.47B | $23.50B | $22.54B | $22.57B | $19.82B | $21.86B | $20.78B | $20.60B | $17.70B | $19.40B | $19.27B | $12.71B | $10.26B |
Total Current Liabilities | $43.06B | $41.91B | $41.52B | $37.84B | $34.77B | $32.24B | $27.59B | $29.54B | $32.71B | $34.47B | $32.52B | $35.19B | $28.53B | $28.68B | $31.95B | $28.66B | $24.18B | $24.65B | $16.47B | $15.59B |
Long Term Debt | $58.51B | $58.05B | $63.80B | $52.96B | $55.63B | $55.81B | $59.29B | $59.91B | $60.40B | $61.00B | $63.52B | $64.93B | $74.05B | $74.24B | $74.18B | $78.41B | $82.28B | $82.06B | $63.28B | $63.25B |
Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Deferred Tax Liabilities Non-Current | $2.75B | $2.73B | $2.72B | $1.95B | $2.04B | $2.12B | $2.11B | $2.19B | $1.97B | $2.25B | $2.83B | $3.01B | $3.60B | $3.66B | $3.77B | $3.65B | $4.49B | $4.79B | $959.00M | $1.13B |
Other Non-Current Liabilities | $33.03B | $32.43B | $32.78B | $33.52B | $31.64B | $32.29B | $32.25B | $32.07B | $30.21B | $30.77B | $28.02B | $30.97B | $29.10B | $28.80B | $26.87B | $30.40B | $23.38B | $23.31B | $17.90B | $18.46B |
Total Non-Current Liabilities | $94.29B | $93.20B | $99.31B | $86.47B | $89.32B | $90.23B | $93.65B | $91.98B | $92.59B | $94.03B | $94.38B | $95.90B | $106.75B | $106.69B | $104.82B | $108.81B | $110.15B | $110.15B | $82.14B | $81.70B |
Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $137.35B | $135.12B | $140.83B | $124.31B | $124.09B | $122.47B | $121.24B | $121.52B | $125.30B | $128.50B | $126.90B | $131.09B | $135.28B | $135.38B | $136.77B | $137.47B | $134.33B | $134.80B | $98.61B | $97.29B |
Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M | $18.00M |
Retained Earnings | $-4.96B | $-3.77B | $-2.38B | $-1.00B | $933.00M | $1.79B | $2.39B | $4.78B | $4.95B | $3.52B | $5.10B | $3.13B | $1.60B | $740.00M | $2.29B | $1.05B | $3.33B | $3.13B | $5.97B | $4.72B |
Accumulated Other Comprehensive Income Loss | $-2.33B | $-2.51B | $-2.45B | $-2.31B | $-2.35B | $-2.25B | $-2.23B | $-2.20B | $-3.44B | $-3.20B | $-2.98B | $-2.90B | $-3.16B | $-3.10B | $-3.29B | $-3.12B | $-3.26B | $-3.44B | $-3.70B | $-3.60B |
Other Total Stockholders Equity | $13.31B | $13.04B | $12.83B | $13.65B | $13.50B | $13.31B | $13.10B | $14.65B | $14.47B | $14.31B | $14.15B | $15.16B | $15.09B | $14.91B | $14.70B | $15.12B | $15.18B | $14.99B | $-9.71B | $-9.31B |
Total Stockholders Equity | $6.03B | $6.78B | $8.01B | $10.36B | $12.09B | $12.87B | $13.27B | $17.25B | $15.99B | $14.65B | $16.28B | $15.41B | $13.55B | $12.57B | $13.71B | $13.08B | $15.27B | $14.71B | $-7.42B | $-8.17B |
Total Equity | $6.07B | $6.82B | $8.05B | $10.40B | $12.13B | $12.90B | $13.30B | $17.29B | $16.03B | $14.69B | $16.31B | $15.44B | $13.58B | $12.59B | $13.73B | $13.10B | $15.29B | $14.73B | $-7.42B | $-8.17B |
Total Liabilities and Stockholders Equity | $143.42B | $141.94B | $148.87B | $134.71B | $136.22B | $135.37B | $134.54B | $138.81B | $141.32B | $143.19B | $143.21B | $146.53B | $148.86B | $147.97B | $150.50B | $150.56B | $149.62B | $149.53B | $91.20B | $89.11B |
Minority Interest | $39.00M | $43.00M | $40.00M | $37.00M | $35.00M | $32.00M | $29.00M | $33.00M | $33.00M | $35.00M | $31.00M | $28.00M | $27.00M | $25.00M | $23.00M | $21.00M | $19.00M | $24.00M | $- | $- |
Total Liabilities and Total Equity | $143.42B | $141.94B | $148.87B | $134.71B | $136.22B | $135.37B | $134.54B | $138.81B | $141.32B | $143.19B | $143.21B | $146.53B | $148.86B | $147.97B | $150.50B | $150.56B | $149.62B | $149.53B | $91.20B | $89.11B |
Total Investments | $295.00M | $299.00M | $307.00M | $306.00M | $278.00M | $295.00M | $268.00M | $269.00M | $282.00M | $1.68B | $1.73B | $361.00M | $339.00M | $320.00M | $327.00M | $323.00M | $306.00M | $248.00M | $78.00M | $93.00M |
Total Debt | $71.08B | $70.63B | $74.00B | $59.38B | $60.75B | $61.02B | $62.09B | $63.27B | $69.61B | $72.93B | $73.47B | $76.68B | $80.72B | $82.14B | $85.53B | $86.06B | $87.06B | $87.43B | $67.05B | $66.73B |
Net Debt | $63.82B | $57.50B | $55.93B | $46.57B | $47.46B | $52.26B | $55.38B | $54.07B | $57.77B | $64.41B | $67.38B | $66.94B | $68.54B | $73.59B | $75.78B | $77.61B | $79.17B | $81.42B | $25.90B | $26.80B |
Annual Cash Flow
Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|
Net Income | $4.87B | $11.85B | $11.55B | $4.62B | $7.88B |
Depreciation and Amortization | $8.70B | $8.47B | $8.52B | $6.47B | $2.02B |
Deferred Income Tax | $-2.89B | $-1.93B | $-898.00M | $-2.33B | $700.00M |
Stock Based Compensation | $747.00M | $671.00M | $692.00M | $753.00M | $430.00M |
Change in Working Capital | $2.81B | $-258.00M | $-1.32B | $106.00M | $-1.33B |
Accounts Receivables | $66.00M | $-1.46B | $-1.32B | $-929.00M | $-74.00M |
Inventory | $-417.00M | $-686.00M | $-142.00M | $-40.00M | $-231.00M |
Accounts Payables | $3.84B | $1.60B | $1.63B | $1.51B | $-1.12B |
Other Working Capital | $-676.00M | $278.00M | $-1.49B | $-439.00M | $97.00M |
Other Non Cash Items | $8.60B | $6.15B | $4.24B | $7.96B | $3.62B |
Net Cash Provided by Operating Activities | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B |
Investments in Property Plant and Equipment | $-777.00M | $-695.00M | $-787.00M | $-798.00M | $-552.00M |
Acquisitions Net | $-1.22B | $-794.00M | $-1.90B | $-39.61B | $-1.14B |
Purchases of Investments | $-77.00M | $-1.44B | $-119.00M | $-61.00M | $-583.00M |
Sales Maturities of Investments | $55.00M | $1.53B | $98.00M | $1.52B | $2.70B |
Other Investing Activities | $13.00M | $774.00M | $366.00M | $1.39B | $167.00M |
Net Cash Used for Investing Activities | $-2.01B | $-623.00M | $-2.34B | $-37.56B | $596.00M |
Debt Repayment | $-4.15B | $-12.43B | $-8.41B | $-2.68B | $26.25B |
Common Stock Issued | $- | $- | $- | $- | $- |
Common Stock Repurchased | $-1.97B | $-1.49B | $-934.00M | $-978.00M | $-629.00M |
Dividends Paid | $-10.54B | $-10.04B | $-9.26B | $-7.72B | $-6.37B |
Other Financing Activities | $-562.00M | $-840.00M | $-430.00M | $-124.00M | $-544.00M |
Net Cash Used Provided by Financing Activities | $-17.22B | $-24.80B | $-19.04B | $-11.50B | $18.71B |
Effect of Forex Changes on Cash | $5.00M | $-62.00M | $-97.00M | $-5.00M | $7.00M |
Net Change in Cash | $3.61B | $-545.00M | $1.30B | $-31.48B | $32.63B |
Cash at End of Period | $12.81B | $9.20B | $9.75B | $8.45B | $39.92B |
Cash at Beginning of Period | $9.20B | $9.75B | $8.45B | $39.92B | $7.29B |
Operating Cash Flow | $22.84B | $24.94B | $22.78B | $17.59B | $13.32B |
Capital Expenditure | $-777.00M | $-695.00M | $-787.00M | $-798.00M | $-552.00M |
Free Cash Flow | $22.06B | $24.25B | $21.99B | $16.79B | $12.77B |
Cash Flow Charts
Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $1.56B | $1.36B | $1.36B | $826.00M | $1.78B | $2.03B | $241.00M | $2.47B | $3.95B | $928.00M | $4.49B | $4.04B | $3.18B | $769.00M | $3.56B | $38.00M | $2.31B | $-739.00M | $3.01B | $2.80B |
Depreciation and Amortization | $2.08B | $2.08B | $2.07B | $2.08B | $2.23B | $2.26B | $2.13B | $2.16B | $2.21B | $2.05B | $2.05B | $1.98B | $2.13B | $2.20B | $2.21B | $2.06B | $2.29B | $1.55B | $559.00M | $509.00M |
Deferred Income Tax | $-277.00M | $-16.00M | $-389.00M | $-1.39B | $-863.00M | $-368.00M | $-267.00M | $-516.00M | $-621.00M | $-600.00M | $-194.00M | $-745.00M | $-34.00M | $-91.00M | $-28.00M | $-1.83B | $-241.00M | $-257.00M | $- | $-330.00M |
Stock Based Compensation | $181.00M | $218.00M | $348.00M | $125.00M | $130.00M | $179.00M | $313.00M | $132.00M | $126.00M | $107.00M | $306.00M | $129.00M | $135.00M | $159.00M | $269.00M | $136.00M | $162.00M | $236.00M | $219.00M | $79.00M |
Change in Working Capital | $750.00M | $-3.38B | $247.00M | $443.00M | $2.64B | $552.00M | $-825.00M | $843.00M | $1.34B | $-1.16B | $-1.27B | $-1.08B | $1.71B | $-990.00M | $-956.00M | $-922.00M | $965.00M | $149.00M | $-86.00M | $-322.00M |
Accounts Receivables | $344.00M | $178.00M | $-702.00M | $339.00M | $2.00M | $-80.00M | $-195.00M | $-416.00M | $357.00M | $-611.00M | $-785.00M | $-749.00M | $590.00M | $-296.00M | $-866.00M | $-355.00M | $-31.00M | $482.00M | $-1.02B | $133.00M |
Inventory | $-64.00M | $-52.00M | $-75.00M | $96.00M | $-55.00M | $-273.00M | $-185.00M | $-170.00M | $-17.00M | $-114.00M | $-385.00M | $-112.00M | $219.00M | $-62.00M | $-187.00M | $153.00M | $111.00M | $-197.00M | $-107.00M | $170.00M |
Accounts Payables | $267.00M | $-1.70B | $362.00M | $179.00M | $2.55B | $1.57B | $-465.00M | $1.27B | $778.00M | $-190.00M | $-258.00M | $174.00M | $1.15B | $72.00M | $236.00M | $-389.00M | $1.44B | $-599.00M | $1.06B | $-539.00M |
Other Working Capital | $203.00M | $-1.81B | $662.00M | $-171.00M | $142.00M | $-667.00M | $20.00M | $154.00M | $220.00M | $-548.00M | $153.00M | $-397.00M | $-247.00M | $-704.00M | $-139.00M | $-331.00M | $-552.00M | $463.00M | $-19.00M | $-86.00M |
Other Non Cash Items | $1.15B | $7.97B | $5.31B | $2.67B | $1.65B | $1.67B | $2.60B | $2.34B | $602.00M | $1.66B | $-475.00M | $751.00M | $819.00M | $2.84B | $-178.00M | $5.36B | $339.00M | $2.15B | $113.00M | $538.00M |
Net Cash Provided by Operating Activities | $5.45B | $2.27B | $4.04B | $4.75B | $7.57B | $6.32B | $4.19B | $7.43B | $7.60B | $5.00B | $4.91B | $5.08B | $7.93B | $4.89B | $4.88B | $4.85B | $5.83B | $3.09B | $3.81B | $3.27B |
Investments in Property Plant and Equipment | $-249.00M | $-241.00M | $-193.00M | $-205.00M | $-219.00M | $-178.00M | $-175.00M | $-213.00M | $-177.00M | $-143.00M | $-162.00M | $-187.00M | $-217.00M | $-195.00M | $-188.00M | $-279.00M | $-217.00M | $-177.00M | $-125.00M | $-163.00M |
Acquisitions Net | $-8.29B | $-843.00M | $-9.20B | $-553.00M | $-157.00M | $-160.00M | $-353.00M | $-300.00M | $-100.00M | $-209.00M | $-185.00M | $-1.06B | $-492.00M | $-147.00M | $-198.00M | $-400.00M | $-880.00M | $-38.32B | $-12.00M | $-659.00M |
Purchases of Investments | $-24.00M | $-16.00M | $-6.00M | $-34.00M | $-8.00M | $-16.00M | $-19.00M | $-10.00M | $-17.00M | $-5.00M | $-1.41B | $-46.00M | $-17.00M | $-40.00M | $-16.00M | $-14.00M | $-15.00M | $-19.00M | $-13.00M | $-4.00M |
Sales Maturities of Investments | $507.00M | $3.00M | $6.00M | $14.00M | $5.00M | $14.00M | $22.00M | $70.00M | $1.41B | $42.00M | $8.00M | $10.00M | $23.00M | $54.00M | $11.00M | $61.00M | $35.00M | $1.40B | $26.00M | $44.00M |
Other Investing Activities | $-196.00M | $-848.00M | $-196.00M | $-22.00M | $10.00M | $-1.00M | $26.00M | $5.00M | $170.00M | $445.00M | $154.00M | $143.00M | $88.00M | $86.00M | $49.00M | $5.00M | $-72.00M | $1.46B | $-5.00M | $167.00M |
Net Cash Used for Investing Activities | $-8.26B | $-1.10B | $-9.59B | $-800.00M | $-369.00M | $-341.00M | $-499.00M | $-448.00M | $1.29B | $130.00M | $-1.59B | $-1.15B | $-615.00M | $-242.00M | $-342.00M | $-627.00M | $-1.15B | $-35.65B | $-129.00M | $-615.00M |
Debt Repayment | $-403.00M | $-3.35B | $14.86B | $-1.79B | $-2.00M | $-1.00B | $-1.35B | $-6.85B | $-2.70B | $-2.00M | $-2.88B | $-3.75B | $-1.20B | $-3.46B | $- | $-1.27B | $-651.00M | $- | $- | $28.42B |
Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Common Stock Repurchased | $-17.00M | $-9.00M | $-1.32B | $-3.00M | $-4.00M | $-10.00M | $-1.96B | $-4.00M | $-4.00M | $-9.00M | $-1.47B | $-131.00M | $-6.00M | $-10.00M | $-787.00M | $-296.00M | $-20.00M | $-19.00M | $-643.00M | $-2.00M |
Dividends Paid | $-2.75B | $-2.75B | $-2.77B | $-2.63B | $-2.63B | $-2.62B | $-2.66B | $-2.51B | $-2.50B | $-2.51B | $-2.53B | $-2.31B | $-2.31B | $-2.31B | $-2.32B | $-2.10B | $-2.10B | $-1.75B | $-1.76B | $-1.59B |
Other Financing Activities | $99.00M | $10.00M | $52.00M | $-26.00M | $-28.00M | $-283.00M | $-225.00M | $-273.00M | $-309.00M | $-161.00M | $-97.00M | $-141.00M | $-121.00M | $-103.00M | $-65.00M | $-29.00M | $-43.00M | $-799.00M | $-16.00M | $-218.00M |
Net Cash Used Provided by Financing Activities | $-3.07B | $-6.10B | $10.82B | $-4.45B | $-2.66B | $-3.92B | $-6.19B | $-9.63B | $-5.52B | $-2.68B | $-6.97B | $-6.34B | $-3.64B | $-5.88B | $-3.17B | $-3.69B | $-2.81B | $-2.57B | $-2.42B | $26.60B |
Effect of Forex Changes on Cash | $8.00M | $-9.00M | $-18.00M | $23.00M | $-16.00M | $-10.00M | $8.00M | $23.00M | $-59.00M | $-33.00M | $7.00M | $-28.00M | $-41.00M | $27.00M | $-55.00M | $27.00M | $6.00M | $8.00M | $-46.00M | $14.00M |
Net Change in Cash | $-5.87B | $-4.94B | $5.25B | $-473.00M | $4.53B | $2.05B | $-2.49B | $-2.63B | $3.31B | $2.42B | $-3.65B | $-2.44B | $3.64B | $-1.21B | $1.31B | $559.00M | $1.87B | $-35.12B | $1.22B | $29.28B |
Cash at End of Period | $7.26B | $13.13B | $18.07B | $12.81B | $13.29B | $8.76B | $6.71B | $9.20B | $11.83B | $8.52B | $6.10B | $9.75B | $12.18B | $8.55B | $9.76B | $8.45B | $7.89B | $6.02B | $41.14B | $39.92B |
Cash at Beginning of Period | $13.13B | $18.07B | $12.81B | $13.29B | $8.76B | $6.71B | $9.20B | $11.83B | $8.52B | $6.10B | $9.75B | $12.18B | $8.55B | $9.76B | $8.45B | $7.89B | $6.02B | $41.14B | $39.92B | $10.65B |
Operating Cash Flow | $5.45B | $2.27B | $4.04B | $4.75B | $7.57B | $6.32B | $4.19B | $7.43B | $7.60B | $5.00B | $4.91B | $5.08B | $7.93B | $4.89B | $4.88B | $4.85B | $5.83B | $3.09B | $3.81B | $3.27B |
Capital Expenditure | $-249.00M | $-241.00M | $-193.00M | $-205.00M | $-219.00M | $-178.00M | $-175.00M | $-213.00M | $-177.00M | $-143.00M | $-162.00M | $-187.00M | $-217.00M | $-195.00M | $-188.00M | $-279.00M | $-217.00M | $-177.00M | $-125.00M | $-163.00M |
Free Cash Flow | $5.20B | $2.03B | $3.85B | $4.55B | $7.36B | $6.14B | $4.02B | $7.21B | $7.42B | $4.86B | $4.75B | $4.89B | $7.72B | $4.70B | $4.69B | $4.58B | $5.61B | $2.91B | $3.69B | $3.11B |
AbbVie Stock Forecast
Analyst ratings, price targets, and earnings estimates for ABBV.
ABBV Analyst Ratings
Moderate Buy
Based on 32 analysts in the past 3 months
ABBV Stock 12 Month Forecast
$214.33
Based on 3 analysts in the last 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|---|---|---|---|---|
Feb 03, 2025 | Gary Nachman | Raymond James | $220.00 | $190.14 | 15.7% |
Feb 03, 2025 | Evan Seigerman | BMO Capital | $215.00 | $190.14 | 13.1% |
Nov 12, 2024 | Evan David Seigerman | BMO Capital | $208.00 | $201.61 | 3.2% |
Oct 31, 2024 | Evan David Seigerman | BMO Capital | $228.00 | $201.50 | 13.2% |
Oct 31, 2024 | Charlie Yang | Bank of America Securities | $210.00 | $201.50 | 4.2% |
Oct 31, 2024 | Geoff Meacham | Citigroup | $226.00 | $201.50 | 12.2% |
Oct 18, 2024 | Geoff Meacham | Bank of America Securities | $195.00 | $188.57 | 3.4% |
Oct 17, 2024 | Courtney Breen | Bernstein | $203.00 | $190.46 | 6.6% |
Aug 23, 2024 | Christopher Raymond | Raymond James | $209.00 | $197.35 | 5.9% |
Jul 19, 2024 | Evan Seigerman | BMO Capital | $214.00 | $172.01 | 24.4% |
AbbVie Dividends
Explore AbbVie's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
3.85%
Dividend Payout Ratio
216.72%
Dividend Paid & Capex Coverage Ratio
2.02x
AbbVie Dividend History
Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|
$1.64 | $1.64 | January 15, 2025 | January 15, 2025 | February 14, 2025 | October 30, 2024 |
$1.55 | $1.55 | October 15, 2024 | October 15, 2024 | November 15, 2024 | September 06, 2024 |
$1.55 | $1.55 | July 15, 2024 | July 15, 2024 | August 15, 2024 | June 20, 2024 |
$1.55 | $1.55 | April 12, 2024 | April 15, 2024 | May 15, 2024 | February 15, 2024 |
$1.55 | $1.55 | January 12, 2024 | January 16, 2024 | February 15, 2024 | October 27, 2023 |
$1.48 | $1.48 | October 12, 2023 | October 13, 2023 | November 15, 2023 | September 08, 2023 |
$1.48 | $1.48 | July 13, 2023 | July 14, 2023 | August 15, 2023 | June 22, 2023 |
$1.48 | $1.48 | April 13, 2023 | April 14, 2023 | May 15, 2023 | February 16, 2023 |
$1.48 | $1.48 | January 12, 2023 | January 13, 2023 | February 15, 2023 | October 28, 2022 |
$1.41 | $1.41 | October 13, 2022 | October 14, 2022 | November 15, 2022 | September 09, 2022 |
$1.41 | $1.41 | July 14, 2022 | July 15, 2022 | August 15, 2022 | June 23, 2022 |
$1.41 | $1.41 | April 13, 2022 | April 15, 2022 | May 16, 2022 | February 17, 2022 |
$1.41 | $1.41 | January 13, 2022 | January 14, 2022 | February 15, 2022 | October 29, 2021 |
$1.3 | $1.3 | October 14, 2021 | October 15, 2021 | November 15, 2021 | September 10, 2021 |
$1.3 | $1.3 | July 14, 2021 | July 15, 2021 | August 16, 2021 | June 17, 2021 |
$1.3 | $1.3 | April 14, 2021 | April 15, 2021 | May 14, 2021 | February 18, 2021 |
$1.3 | $1.3 | January 14, 2021 | January 15, 2021 | February 16, 2021 | October 30, 2020 |
$1.18 | $1.18 | October 14, 2020 | October 15, 2020 | November 16, 2020 | September 11, 2020 |
$1.18 | $1.18 | July 14, 2020 | July 15, 2020 | August 14, 2020 | June 17, 2020 |
$1.18 | $1.18 | April 14, 2020 | April 15, 2020 | May 15, 2020 | February 20, 2020 |
Peers: Drug Manufacturers - General
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() Merck & Co., Inc.
MRK
|
$223.05B | $88.17 | $0.14 | $778.71 | $7.56 |
![]() Pfizer Inc.
PFE
|
$146.77B | $25.90 | $0.38 | $76.67 | $1.83 |
![]() Eli Lilly and Company
LLY
|
$828.37B | $872.60 | $5.83 | $100.04 | $48.67 |
![]() Bristol-Myers Squibb Company
BMY
|
$116.72B | $57.55 | $3.88 | $13.23 | $3.61 |
![]() Johnson & Johnson
JNJ
|
$369.43B | $153.44 | $13.88 | $11.30 | $5.77 |
![]() Amgen Inc.
AMGN
|
$160.02B | $297.70 | $7.62 | $34.22 | $0.00 |
![]() Gilead Sciences, Inc.
GILD
|
$123.02B | $98.71 | $4.54 | $17.85 | $4.43 |
Related Metrics
Explore detailed financial metrics and analysis for ABBV.